Literature DB >> 27166684

The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.

Sofia Carvalho Barreira1,2, João Eurico Fonseca3,4.   

Abstract

The bone and the immune system have a very tight interaction. Systemic immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), induce bone loss, leading to a twofold increase in osteoporosis and an increase of fragility fracture risk of 1.35-2.13 times. This review focuses on the effects of conventional and biological disease modifying antirheumatic drugs (DMARDs) on bone biology, in the context of systemic inflammation, with a focus on RA. Published evidence supports a decrease in osteoclastic activity induced by DMARDs, which leads to positive effects on bone mineral density (BMD). It is unknown if this effect could be translated into fracture risk reduction. The combination with antiosteoclastic drugs can have an additional benefit.

Entities:  

Keywords:  Bone; DMARDs; RA

Mesh：

Substances：

Year:  2016        PMID： 27166684     DOI： 10.1007/s12016-016-8547-6

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


  70 in total

Review 1.  Wnt signaling in bone metabolism.

Authors:  Takuo Kubota; Toshimi Michigami; Keiichi Ozono
Journal:  J Bone Miner Metab       Date:  2009-03-31       Impact factor: 2.626

2.  The in vitro effect of gold complexes on bone resorption.

Authors:  J M Katz; D H Gray
Journal:  J Orthop Res       Date:  1986       Impact factor: 3.494

3.  JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

Authors:  Timothy P LaBranche; Michael I Jesson; Zaher A Radi; Chad E Storer; Julia A Guzova; Sheri L Bonar; Janice M Thompson; Fernando A Happa; Zachary S Stewart; Yutian Zhan; Chris S Bollinger; Prashant N Bansal; Jeremy W Wellen; Dean P Wilkie; Steven A Bailey; Peter T Symanowicz; Martin Hegen; Richard D Head; Nandini Kishore; Gabriel Mbalaviele; Debra M Meyer
Journal:  Arthritis Rheum       Date:  2012-11

4.  Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.

Authors:  Sundaram G Veerappan; Martin Healy; Bernard J Walsh; Colm A O'Morain; Jacqueline S Daly; Barbara M Ryan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

5.  CTLA-4 directly inhibits osteoclast formation.

Authors:  R Axmann; S Herman; M Zaiss; S Franz; K Polzer; J Zwerina; M Herrmann; J Smolen; G Schett
Journal:  Ann Rheum Dis       Date:  2008-01-18       Impact factor: 19.103

6.  Serum Sclerostin Level Among Egyptian Rheumatoid Arthritis Patients: Relation to Disease Activity, Bone Mineral Density and Radiological Grading.

Authors:  D A Mehaney; M Eissa; S Anwar; S Fakhr El-Din
Journal:  Acta Reumatol Port       Date:  2015 Jul-Sep       Impact factor: 1.290

Review 7.  Osteoimmunology--the hidden immune regulation of bone.

Authors:  J Caetano-Lopes; H Canhão; J E Fonseca
Journal:  Autoimmun Rev       Date:  2008-08-21       Impact factor: 9.754

8.  IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17.

Authors:  Toru Yago; Yuki Nanke; Naomi Ichikawa; Tsuyoshi Kobashigawa; Makio Mogi; Naoyuki Kamatani; Shigeru Kotake
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

9.  Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate.

Authors:  Aase Haj Hensvold; Vijay Joshua; Wanying Li; Michaela Larkin; Ferhan Qureshi; Lena Israelsson; Leonid Padyukov; Karin Lundberg; Nadine Defranoux; Saedis Saevarsdottir; Anca Irinel Catrina
Journal:  Arthritis Res Ther       Date:  2015-09-04       Impact factor: 5.156

10.  Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis.

Authors:  Xiao-Xiang Chen; Wolfgang Baum; Denise Dwyer; Michael Stock; Kay Schwabe; Hua-Zhu Ke; Marina Stolina; Georg Schett; Aline Bozec
Journal:  Ann Rheum Dis       Date:  2013-05-10       Impact factor: 19.103
View more
  6 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

Review 2.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

3.  Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.

Authors:  Shangyi Jin; Mengtao Li; Yongfei Fang; Qin Li; Ju Liu; Xinwang Duan; Yi Liu; Rui Wu; Xiaofei Shi; Yongfu Wang; Zhenyu Jiang; Yanhong Wang; Chen Yu; Qian Wang; Xinping Tian; Yan Zhao; Xiaofeng Zeng
Journal:  Arthritis Res Ther       Date:  2017-11-15       Impact factor: 5.156

Review 4.  Osteoporosis in Rheumatic Diseases.

Authors:  Giovanni Adami; Angelo Fassio; Maurizio Rossini; Cristian Caimmi; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

5.  The Systemic Immune Response to Collagen-Induced Arthritis and the Impact of Bone Injury in Inflammatory Conditions.

Authors:  José H Teixeira; Andreia M Silva; Maria Inês Almeida; Mafalda Bessa-Gonçalves; Carla Cunha; Mário A Barbosa; Susana G Santos
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

6.  Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway.

Authors:  Chenyi Ye; Wei Zhang; Kai Hang; Mo Chen; Weiduo Hou; Jianzhong Chen; Xi Chen; Erman Chen; Lan Tang; Jinwei Lu; Qianhai Ding; Guangyao Jiang; Baojian Hong; Rongxin He
Journal:  Cell Death Dis       Date:  2019-10-03       Impact factor: 8.469
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.